This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abilify (Oral and IM)
Bristol-Myers Squibb Company
Drug Names(s): Abilify Discmelt, OPC-14597, BMS-337039, Captisol-enabled IM (intramuscular) Aripiprazole
BioMedTracker has separate drug profiles for the oral/intramuscular (IM) and IM depot formulations of aripiprazole. Please also see Aripiprazole Maintena.
Abilify belongs to a new class of drugs called atypical antipsychotics, though it is different from other atypical agents because it is a partial agonist at the dopamine D-2 receptor, rather than an antagonist, and does not have a lower affinity there than at the serotonin 5-HT2A receptor. Its antipsychotic effect is thought to occur through blockade of D-2 receptors in the ventral striatum, and the partial agonism is though to reduce side effects of stronger D-2 blockade, especially motor function side effects caused by blockade of D-2 receptors in the dorsal striatum). By blocking overstimulated receptors and stimulating underactive ones, partial D2 agonists act as dopamine stabilizers.
Abilify has high affinity for dopamine D2 and D3, serotonin 5-HT1A (partial agonist) and 5-HT2A receptors (antagonist), moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors, and moderate affinity for the serotonin reuptake site. Abilify has no appreciable affinity for cholinergic muscarinic receptors.
Revenue splits for this drug are BioMedTracker estimates.
The historical revenue here represents the contractual share of Abilify net sales recognized by Bristol-Myers Squibb.
Otsuka and Bristol-Myers Squibb
Aripiprazole was developed originally by Otsuka Pharmaceutical. In September 1999, Bristol-Myers Squibb and Otsuka Pharmaceutical announced a development, commercialization and collaboration agreement for aripiprazole. Under terms of the agreement, Bristol-Myers Squibb will market and promote aripiprazole, in collaboration with Otsuka and under Otsuka's trademark, in the U.S. and the European Union. Outside of these markets, excluding Japan and some Asian and Middle-Eastern countries, Bristol-Myers Squibb will have the exclusive license to develop and market aripiprazole. Otsuka and Bristol-Myers Squibb will collaborate to complete the clinical studies for schizophrenia, and Bristol-Myers Squibb will conduct additional studies for new dosage forms and...See full deal structure in Biomedtracker
Partners: Otsuka Holdings Co., Ltd. Ligand Pharmaceuticals, Inc. H. Lundbeck A/S
Abilify (Oral and IM) News
Additional information available to subscribers only: